Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promise of CD20xCD3 bispecific antibodies, such as glofitamab and epcoritamab, in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas, particularly those who relapse after CAR-T therapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть